Drugs / Autologous mesenchymal stem cells derived from bone marrow
Autologous mesenchymal stem cells derived from bone marrow
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01919827 | Mar 2013 → May 2018 | idiopathic pulmonary fibrosis | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous mesenchymal stem cells derived from bone marrow | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01919827 ↗ |
| Known as | BM-MSC | “bone marrow autologous MSCs (BM-MSC)” PMID 34195252 ↗ Jun 2021 |
| Known as | BM-MSCs | “autologous adult BM-MSCs” PMID 34195252 ↗ Jun 2021 |
| Known as | MSCs | “bone marrow autologous MSCs (BM-MSC)” PMID 34195252 ↗ Jun 2021 |
| Route | Other | “single endobronchial administration of autologous adult BM-MSCs” PMID 34195252 ↗ Jun 2021 |